^
Association details:
| Biomarker: | PIK3CA E545K |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Estybon (rigosertib) (PI3K inhibitor, PLK1 inhibitor, RAS antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas
Excerpt:
A heterozygous E545K substitution in PI3KCA was identified in CUHN026 xenograft. This variant has been catalogued as an activating mutation located within the helical domain (41). Growth of CUHN026 was reduced with rigosertib treatment, consistent with our hypothesis that rigosertib treatment will have a more potent effect in the presence of PI3K pathway activation.
DOI:
10.1158/1535-7163.MCT-13-0206
